Targeted nanoparticles with novel non-peptidic ligands for oral delivery

Advanced Drug Delivery Reviews

Volumn 65, Issue 6, 2013, Pages 833-844

  des Rieux, Anne ^a   Pourcelle, Vincent ^a   Cani, Patrice D ^a   Marchand Brynaert, Jacqueline ^a   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Ligand; Nanoparticles; Non peptidic ligand; Oral delivery; Targeting

Indexed keywords

BIOMEDICAL APPLICATIONS; GASTROINTESTINAL TRACT; GRAFTED NANOPARTICLES; INTESTINAL EPITHELIUM; ORAL DELIVERY; PARTICLE SIZE AND SURFACES; PEPTIDIC LIGANDS; TARGETING;

CELLS; CYTOLOGY; DRUG DELIVERY; GRAFTING (CHEMICAL); MEDICAL APPLICATIONS; NANOPARTICLES; PROTEINS; SURFACE PROPERTIES;

LIGANDS;

CIPROFLOXACIN; CYANOCOBALAMIN; G PROTEIN COUPLED RECEPTOR; NANOPARTICLE; POLYGLACTIN; POLYLACTIC ACID; SHORT CHAIN FATTY ACID; THIAMINE; VITRONECTIN RECEPTOR;

ANTIGEN PRESENTING CELL; BINDING AFFINITY; CELL TYPE; CELLULAR DISTRIBUTION; DENDRITIC CELL; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; GASTROINTESTINAL TRACT; GOBLET CELL; GRAM NEGATIVE INFECTION; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INTESTINE CELL; LIGAND BINDING; MICROFOLD CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PEPTIDOMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURFACE PROPERTY; TARGET CELL; TRANSCYTOSIS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CARBOHYDRATES; DRUG CARRIERS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; NANOPARTICLES; PARTICLE SIZE; PROTEINS; RECEPTORS, CELL SURFACE; VITAMINS;

EID: 84878835640     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.01.002     Document Type: Review

References (124)

1. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116:1-27.
2. Florence A.T. Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov. Today Technol. 2005, 2:75-81.
3. McNeela E.A., Lavelle E.C. Recent Advances in Microparticle and Nanoparticle Delivery Vehicles for Mucosal Vaccination Mucosal Vaccines 2012, 75-99. Springer, Berlin Heidelberg. P.A. Kozlowski (Ed.).
4. Mrsny R.J. Oral drug delivery research in Europe. J. Control. Release 2012, 161:247-253.
5. O'Donnell K.P., Williams R.O. Nanoparticulate systems for oral drug delivery to the colon. Int. J. Nanotechnol. 2011, 8:4-20.
6. Plapied L., Duhem N., des Rieux A., Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 2011, 16:228-237.
7. Petros R.A., Desimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
8. Lu J.M., Wang X., Marin-Muller C., Wang H., Lin P.H., Yao Q., Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 2009, 9:325-341.
9. Agueros M., Espuelas S., Esparza I., Calleja P., Penuelas I., Ponchel G., Irache J.M. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. Expert Opin. Drug Deliv. 2011, 8:721-734.
10. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 2010, 62:59-82.
11. Park J.H., Saravanakumar G., Kim K., Kwon I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 2010, 62:28-41.
12. Werle M., Takeuchi H., Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J. Pharm. Sci. 2009, 98:1643-1656.
13. Ensign L.M., Schneider C., Suk J.S., Cone R., Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv. Mater. 2012, 24:3887-3894.
14. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
15. Chen M.C., Sonaje K., Chen K.J., Sung H.W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
16. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 2009, 66:2873-2896.
17. Florence A.T. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. J. Control. Release 2012, 164:115-124.
18. Devriendt B., De Geest B.G., Goddeeris B.M., Cox E. Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. J. Control. Release 2012, 160:431-439.
19. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012, 14:282-295.
20. Zhang B., Yan B. Analytical strategies for characterizing the surface chemistry of nanoparticles. Anal. Bioanal. Chem. 2010, 396:973-982.
21. Valencia P.M., Hanewich-Hollatz M.H., Gao W., Karim F., Langer R., Karnik R., Farokhzad O.C. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011, 32:6226-6233.
22. Bandyopadhyay A., Fine R.L., Demento S., Bockenstedt L.K., Fahmy T.M. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011, 32:3094-3105.
23. Park J., Mattessich T., Jay S.M., Agawu A., Saltzman W.M., Fahmy T.M. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J. Control. Release 2011, 156:109-115.
24. Sawant R.R., Sawant R.M., Kale A.A., Torchilin V.P. The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J. Drug Target. 2008, 16:596-600.
25. Wang S., Dormidontova E.E. Nanoparticle design optimization for enhanced targeting: Monte Carlo simulations. Biomacromolecules 2010, 11:1785-1795.
26. Brandhonneur N., Chevanne F., Vie V., Frisch B., Primault R., Le Potier M.F., Le C.P. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 2009, 36:474-485.
27. Croll T.I., O'Connor A.J., Stevens G.W., Cooper-White J.J. Controllable surface modification of poly(lactic-co-glycolic acid) (PLGA) by hydrolysis or aminolysis I: physical, chemical, and theoretical aspects. Biomacromolecules 2004, 5:463-473.
28. Freichels H., Pourcelle V., Le Duff C.S., Marchand-Brynaert J., JérÔme C. "Clip" and "click" chemistries combination: toward easy PEGylation of degradable aliphatic polyesters. Macromol. Rapid Commun. 2011, 32:616-621.
29. Freichels H., Pourcelle V., Auzely-Velty R., Marchand-Brynaert J., JérÔme C. Synthesis of poly(lactide-co-glycolide-co-epsilon-caprolactone)-graft-mannosylated poly(ethylene oxide) copolymers by combination of "clip" and "click" chemistries. Biomacromolecules 2012, 13:760-768.
30. Salman H.H., Gamazo C., de Smidt P.C., Russell-Jones G., Irache J.M. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B(12)-Gantrez nanoparticles. Pharm. Res. 2008, 25:2859-2868.
31. Danhier F., Breton A.L., Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 2012, 9:2961-2973.
32. Garinot M., Fievez V., Pourcelle V., Stoffelbach F., des Rieux A., Plapied L., Theate I., Freichels H., JérÔme C., Marchand-Brynaert J., Schneider Y.J., Préat V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 2007, 120:195-204.
33. Heckmann D., Meyer A., Laufer B., Zahn G., Stragies R., Kessler H. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem 2008, 9:1397-1407.
34. Carlson C.B., Mowery P., Owen R.M., Dykhuizen E.C., Kiessling L.L. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2007, 2:119-127.
35. Merkel O.M., Germershaus O., Wada C.K., Tarcha P.J., Merdan T., Kissel T. Integrin alphaVbeta3 targeted gene delivery using RGD peptidomimetic conjugates with copolymers of PEGylated poly(ethylene imine). Bioconjug. Chem. 2009, 20:1270-1280.
36. 3 receptor-ligand interactions. Macromolecules 2004, 37:7109-7115.
37. Winter P.M., Schmieder A.H., Caruthers S.D., Keene J.L., Zhang H., Wickline S.A., Lanza G.M. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008, 22:2758-2767.
38. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., Zhang Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control. Release 2005, 107:262-275.
39. Fievez V., Plapied L., des Rieux A., Pourcelle V., Freichels H., Wascotte V., Vanderhaeghen M.L., JérÔme C., Vanderplasschen A., Marchand-Brynaert J., Schneider Y.J., Préat V. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm. 2009, 73:16-24.
40. Rerat V., Dive G., Cordi A.A., Tucker G.C., Bareille R., Amedee J., Bordenave L., Marchand-Brynaert J. alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J. Med. Chem. 2009, 52:7029-7043.
41. Rémy M., Bareille R., Rerat V., Bourget C., Marchand-Brynaert J., Bordenave L. Polyethylene terephthalate membrane grafted with peptidomimetics: endothelial cell compatibility and retention under shear stress. J. Biomater. Sci. Polym. Ed. 2012, 1-18.
42. Pourcelle V., Freichels H., Stoffelbach F., Auzely-Velty R., JérÔme C., Marchand-Brynaert J. Light induced functionalization of PCL-PEG block copolymers for the covalent immobilization of biomolecules. Biomacromolecules 2009, 10:966-974.
43. Pourcelle V., Devouge S., Garinot M., Préat V., Marchand-Brynaert J. PCL-PEG-based nanoparticles grafted with GRGDS peptide: preparation and surface analysis by XPS. Biomacromolecules 2007, 8:3977-3983.
44. Momtaz M., Rerat V., Gharbi S., Gerard E., Pourcelle V., Marchand-Brynaert J. A graftable LDV peptidomimetic: design, synthesis and application to a blood filtration membrane. Bioorg. Med. Chem. Lett. 2008, 18:1084-1090.
45. Irache J.M., Salman H.H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 2008, 5:703-724.
46. Freichels H., JérÔme R., JérÔme C. Sugar-labeled and PEGylated (bio)degradable polymers intended for targeted drug delivery systems. Carbohydr. Polym. 2011, 86:1093-1106.
47. Jain K., Kesharwani P., Gupta U., Jain N.K. A review of glycosylated carriers for drug delivery. Biomaterials 2012, 33:4166-4186.
48. Slavin S., Burns J., Haddleton D.M., Becer C.R. Synthesis of glycopolymers via click reactions. Eur. Polym. J. 2011, 47:435-446.
49. Rieger J., Stoffelbach F., Cui D., Imberty A., Lameignere E., Putaux J.L., JérÔme R., JérÔme C., Auzely-Velty R. Mannosylated poly(ethylene oxide)-b-poly(epsilon-caprolactone) diblock copolymers: synthesis, characterization, and interaction with a bacterial lectin. Biomacromolecules 2007, 8:2717-2725.
50. Rieger J., Freichels H., Imberty A., Putaux J.L., Delair T., JérÔme C., Auzely-Velty R. Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties. Biomacromolecules 2009, 10:651-657.
51. Freichels H., Auzely-Velty R., Lecomte P., JérÔme C. Easy functionalization of amphiphilic poly(ethylene oxide)-b-poly(e-caprolactone) copolymer micelles with unprotected sugar: synthesis and recognition by lectins. Polym. Chem. 2012, 3:1436-1445.
52. Xu N., Wang R., Du F.S., Li Z.C. Synthesis of amphiphilic biodegradable glycocopolymers based on poly(ε-caprolactone) by ring-opening polymerization and click chemistry. J. Polym. Sci. A Polym. Chem. 2009, 47:3583-3594.
53. Nagasaki Y., Yasugi K., Yamamoto Y., Harada A., Kataoka K. Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules 2001, 2:1067-1070.
54. Hamdy S., Haddadi A., Shayeganpour A., Samuel J., Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res. 2011, 28:2288-2301.
55. Jule E., Nagasaki Y., Kataoka K. Lactose-installed poly(ethylene glycol)-poly(d, l-lactide) block copolymer micelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug. Chem. 2003, 14:177-186.
56. Du F., Zhang B., Zhou H., Yan B., Chen L. Structure elucidation of nanoparticle-bound organic molecules by 1H NMR. Trends Anal. Chem. 2009, 28:88-95.
57. Du Y.R., Zhao S., Shen L.F. Nuclear magnetic resonance studies of micelles. Annual Reports on NMR Spectroscopy 2002, 145-194. Academic Press.
58. Pourcelle V., Le Duff C.S., Freichels H., JérÔme C., Marchand-Brynaert J. Clickable PEG conjugate obtained by "clip[U+F022]" photochemistry: synthesis and characterization by quantitative 19F NMR. J. Fluor. Chem. 2012, 140:62-69.
59. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog. 2010, 6:e1001147.
60. Brayden D.J., Jepson M.A., Baird A.W. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 2005, 10:1145-1157.
61. Corr S.C., Gahan C.C., Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol. 2008, 52:2-12.
62. Demento S.L., Siefert A.L., Bandyopadhyay A., Sharp F.A., Fahmy T.M. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 2011, 29:294-306.
63. Akalkotkar A., Tawde S.A., Chablani L., D'Souza M.J. Oral delivery of particulate prostate cancer vaccine: in vitro and in vivo evaluation. J. Drug Target. 2012, 20:338-346.
64. Fievez V., Plapied L., Plaideau C., Legendre D., des Rieux A., Pourcelle V., Freichels H., JérÔme C., Marchand J., Préat V., Schneider Y.J. In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 2010, 394:35-42.
65. Gullberg E., Soderholm J.D. Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease. Ann. N. Y. Acad. Sci. 2006, 1072:218-232.
66. Gupta P.N., Khatri K., Goyal A.K., Mishra N., Vyas S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 2007, 15:701-713.
67. Gupta P.N., Vyas S.P. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B Biointerfaces 2011, 82:118-125.
68. Misumi S., Masuyama M., Takamune N., Nakayama D., Mitsumata R., Matsumoto H., Urata N., Takahashi Y., Muneoka A., Sukamoto T., Fukuzaki K., Shoji S. Targeted delivery of immunogen to primate M cells with tetragalloyl lysine dendrimer. J. Immunol. 2009, 182:6061-6070.
69. Tyrer P.C., Ruth F.A., Kyd J.M., Otczyk D.C., Cripps A.W. Receptor mediated targeting of M-cells. Vaccine 2007, 25:3204-3209.
70. Hamashin C., Spindler L., Russell S., Schink A., Lambkin I., O'Mahony D., Houghten R., Pinilla C. Identification of novel small-molecule Ulex europaeus I mimetics for targeted drug delivery. Bioorg. Med. Chem. 2003, 11:4991-4997.
71. Pielage J.F., Cichon C., Greune L., Hirashima M., Kucharzik T., Schmidt M.A. Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface marker molecule for human follicle-associated epithelia and M cell-like cells. Int. J. Biochem. Cell Biol. 2007, 39:1886-1901.
72. Lambkin I., Pinilla C., Hamashin C., Spindler L., Russell S., Schink A., Moya-Castro R., Allicotti G., Higgins L., Smith M., Dee J., Wilson C., Houghten R., O'Mahony D. Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm. Res. 2003, 20:1258-1266.
73. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009, 30:3297-3306.
74. Gullberg E., Leonard M., Karlsson J., Hopkins A.M., Brayden D., Baird A.W., Artursson P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 2000, 279:808-813.
75. Gullberg E., Keita A.V., Salim S.Y., Andersson M., Caldwell K.D., Soderholm J.D., Artursson P. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J. Pharmacol. Exp. Ther. 2006, 319:632-639.
76. Gorfu G., Rivera-Nieves J., Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 2009, 9:836-850.
77. Rajapaksa T.E., Stover-Hamer M., Fernandez X., Eckelhoefer H.A., Lo D.D. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Control. Release 2010, 142:196-205.
78. Lo D.D., Ling J., Eckelhoefer A.H. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol. Mar 13 2012, 12:7.
79. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., Kadokura K., Tobe T., Fujimura Y., Kawano S., Yabashi A., Waguri S., Nakato G., Kimura S., Murakami T., Iimura M., Hamura K., Fukuoka S., Lowe A.W., Itoh K., Kiyono H., Ohno H. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
80. Ohno H., Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes 2010, 1:407-410.
81. Fotopoulos G., Harari A., Michetti P., Trono D., Pantaleo G., Kraehenbuhl J.P. Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9410-9414.
82. Helander A., Silvey K.J., Mantis N.J., Hutchings A.B., Chandran K., Lucas W.T., Nibert M.L., Neutra M.R. The viral sigma1 protein and glycoconjugates containing alpha2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces. J. Virol. 2003, 77:7964-7977.
83. Hutchings A.B., Helander A., Silvey K.J., Chandran K., Lucas W.T., Nibert M.L., Neutra M.R. Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J. Virol. 2004, 78:947-957.
84. Rubas W., Banerjea A.C., Gallati H., Speiser P.P., Joklik W.K. Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J. Microencapsul. 1990, 7:385-395.
85. Amerongen H.M., Weltzin R., Farnet C.M., Michetti P., Haseltine W.A., Neutra M.R. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J. Acquir. Immune Defic. Syndr. 1991, 4:760-765.
86. Snoeck V., Van den Broeck W., De Colvenaer V., Verdonck F., Goddeeris B., Cox E. Transcytosis of F4 fimbriae by villous and dome epithelia in F4-receptor positive pigs supports importance of receptor-dependent endocytosis in oral immunization strategies. Vet. Immunol. Immunopathol. 2008, 124:29-40.
87. Tiels P., Verdonck F., Coddens A., Goddeeris B., Cox E. The excretion of F18+ E. coli is reduced after oral immunisation of pigs with a FedF and F4 fimbriae conjugate. Vaccine 2008, 26:2154-2163.
88. Van den Broeck W., Cox E., Goddeeris B.M. Receptor-dependent immune responses in pigs after oral immunization with F4 fimbriae. Infect. Immun. 1999, 67:520-526.
89. Verdonck F., Snoeck V., Goddeeris B.M., Cox E. Cholera toxin improves the F4(K88)-specific immune response following oral immunization of pigs with recombinant FaeG. Vet. Immunol. Immunopathol. 2005, 103:21-29.
90. Salman H.H., Gamazo C., Campanero M.A., Irache J.M. Salmonella-like bioadhesive nanoparticles. J. Control. Release 2005, 106:1-13.
91. Neal M.D., Leaphart C., Levy R., Prince J., Billiar T.R., Watkins S., Li J., Cetin S., Ford H., Schreiber A., Hackam D.J. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J. Immunol. 2006, 176:3070-3079.
92. Liu Y., Wang P., Sun C., Feng N., Zhou W., Yang Y., Tan R., Chen Z., Wu S., Zhao J. Wheat germ agglutinin-grafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2 monolayers. Int. J. Pharm. 2010, 397:155-163.
93. Mishra N., Tiwari S., Vaidya B., Agrawal G.P., Vyas S.P. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J. Drug Target. 2011, 19:67-78.
94. Yin Y., Chen D., Qiao M., Wei X., Hu H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 2007, 123:27-38.
95. Francis M.F., Cristea M., Winnik F.M. Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules 2005, 6:2462-2467.
96. Salman H.H., Gamazo C., Agueros M., Irache J.M. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine 2007, 25:8123-8132.
97. Kang S.K., Woo J.H., Kim M.K., Woo S.S., Choi J.H., Lee H.G., Lee N.K., Choi Y.J. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J. Biotechnol. 2008, 135:210-216.
98. Jin Y., Song Y., Zhu X., Zhou D., Chen C., Zhang Z., Huang Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 2012, 33:1573-1582.
99. Nikitas G., Deschamps C., Disson O., Niault T., Cossart P., Lecuit M. Transcytosis of Listeria monocytogenes across the intestinal barrier upon specific targeting of goblet cell accessible E-cadherin. J. Exp. Med. 2011, 208:2263-2277.
100. Joshi M.D., Unger W.J., Storm G., van Kooyk Y., Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control. Release 2012, 161:25-37.
101. Devriendt B., De Geest B.G., Cox E. Designing oral vaccines targeting intestinal dendritic cells. Expert Opin. Drug Deliv. 2011, 8:467-483.
102. Raghuwanshi D., Mishra V., Kaur K., Suresh M.R. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012, 30:7292-7299.
103. Carrillo-Conde B., Song E.H., Chavez-Santoscoy A., Phanse Y., Ramer-Tait A.E., Pohl N.L., Wannemuehler M.J., Bellaire B.H., Narasimhan B. Mannose-functionalized "pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol. Pharm. 2011, 8:1877-1886.
104. Ghotbi Z., Haddadi A., Hamdy S., Hung R.W., Samuel J., Lavasanifar A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J. Drug Target. 2011, 19:281-292.
105. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 2005, 11:S45-S53.
106. Coco R., Plapied L., Pourcelle V., JérÔme C., Brayden D.J., Schneider Y.J., Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm. 2012.
107. Reimann F., Habib A.M., Tolhurst G., Parker H.E., Rogers G.J., Gribble F.M. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008, 8:532-539.
108. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986, 261:11880-11889.
109. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
110. Rowland K.J., Brubaker P.L. The "cryptic" mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G1-G8.
111. Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., Muir A.I., Wigglesworth M.J., Kinghorn I., Fraser N.J., Pike N.B., Strum J.C., Steplewski K.M., Murdock P.R., Holder J.C., Marshall F.H., Szekeres P.G., Wilson S., Ignar D.M., Foord S.M., Wise A., Dowell S.J. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278:11312-11319.
112. Thangaraju M., Cresci G.A., Liu K., Ananth S., Gnanaprakasam J.P., Browning D.D., Mellinger J.D., Smith S.B., Digby G.J., Lambert N.A., Prasad P.D., Ganapathy V. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009, 69:2826-2832.
113. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
114. Karaki S., Tazoe H., Hayashi H., Kashiwabara H., Tooyama K., Suzuki Y., Kuwahara A. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 2008, 39:135-142.
115. Tazoe H., Otomo Y., Karaki S., Kato I., Fukami Y., Terasaki M., Kuwahara A. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed. Res. 2009, 30:149-156.
116. Cani P.D., Possemiers S., van de Wiele T., Guiot Y., Everard A., Rottier O., Geurts L., Naslain D., Neyrinck A., Lambert D.M., Muccioli G.G., Delzenne N.M. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
117. Lauffer L.M., Iakoubov R., Brubaker P.L. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009, 58:1058-1066.
118. Muccioli G.G., Naslain D., Backhed F., Reigstad C.S., Lambert D.M., Delzenne N.M., Cani P.D. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 2010, 6:392.
119. Thomas C., Gioiello A., Noriega L., Strehle A., Oury J., Rizzo G., Macchiarulo A., Yamamoto H., Mataki C., Pruzanski M., Pellicciari R., Auwerx J., Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009, 10:167-177.
120. Cummings J.H., Pomare E.W., Branch W.J., Naylor C.P., Macfarlane G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987, 28:1221-1227.
121. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., Fukusumi S., Habata Y., Itoh T., Shintani Y., Hinuma S., Fujisawa Y., Fujino M. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278:9435-9440.
122. Katsuma S., Hirasawa A., Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005, 329:386-390.
123. Cipriani S., Mencarelli A., Chini M.G., Distrutti E., Renga B., Bifulco G., Baldelli F., Donini A., Fiorucci S. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 2011, 6:e25637.
124. Talukdar S., Olefsky J.M., Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 2011, 32:543-550.